CD22 and acute lymphoblastic leukemia: Initial in vitro studies using pediatric primary BCP-ALL cells demonstrated that while CD22 expression was necessary for InO uptake, there was no requirement for subsequent renewed CD22 expression to achieve sufficient intracellular levels, suggesting that high doses may not be necessary for therapeutic benefit (23).